CN104367594A - New application of drug residues after alcohol extraction of American cockroach - Google Patents
New application of drug residues after alcohol extraction of American cockroach Download PDFInfo
- Publication number
- CN104367594A CN104367594A CN201410387622.4A CN201410387622A CN104367594A CN 104367594 A CN104367594 A CN 104367594A CN 201410387622 A CN201410387622 A CN 201410387622A CN 104367594 A CN104367594 A CN 104367594A
- Authority
- CN
- China
- Prior art keywords
- medicinal residues
- alcohol
- alcoholic
- liver
- periplaneta americana
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Insects & Arthropods (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention provides new application of drug residues after alcohol extraction of American cockroach in preparation of anti hepatic injury drugs. According to the studies, the drug residues after alcohol extraction of American cockroach are effective on the treatment of hepatic injury, especially alcohol hepatic injury, and improve the utilization rate of the resources of medicinal materials.
Description
Technical field
The present invention relates to the novelty teabag of the medicinal residues after periplaneta americana alcohol extraction.
Background technology
In recent years, the disease that alcohol dependence causes, global quantity sharply increases, and has become the public health problem that the world today is day by day serious
[1].As everyone knows, people's ethanol is taken the photograph in a large number in short time, acute liver damage can be caused, long-term heavy drinking can cause alcoholic liver disease (Alcoholic liver disease, ALD), the sickness rate of ALD is also in the trend risen year by year, and ethanol has become the second largest cause of disease that China causes hepatic injury after viral hepatitis
[2].ALD comprises mild alcoholic liver disease, alcoholic fatty liver, alcoholic hepatitis, alcoholic fibrosis and alcoholic cirrhosis
[3].So become a kind of main Research approach to the active substance finding treatment hepatopathy from Chinese herbal medicine at present.
Periplaneta americana (Periplaneta americana) belongs to Insecta, Blattaria, Blattidae, is commonly called as Blatta seu periplaneta, and nature and flavor are salty, cold; There is effect of removing blood stasis with potent drugs eliminate indigestion, detumescence, removing toxic substances, promoting blood circulation
[4].Since 20 century 70s, the research of domestic scholars to periplaneta americana achieves good progress, and successively develop periplaneta americana series insecticide medicine, as new in rehabilitation, the grand regulating liver-QI of heart arteries and veins is imperial
[5].Along with research deepen continuously, studies have found that American-cockroach-extract have antibacterial (x), antitumor isoreactivity.But, at present to the utilization of periplaneta americana, all concentrate its water extraction or ethanol extract, yet there are no the research of medicinal residues after it is extracted.
Summary of the invention
The object of the present invention is to provide the novelty teabag of medicinal residues after periplaneta americana alcohol extraction.
The invention provides the purposes of medicinal residues in the medicine preparing anti-liver injury after periplaneta americana alcohol extraction.
Further, described hepatic injury is acute liver damage.
Further, described hepatic injury is alcoholic liver injury.
Preferably, described medicine is the medicine for the treatment of alcoholic liver disease, alcoholic fatty liver, alcoholic hepatitis, alcoholic fibrosis or alcoholic cirrhosis.
Further, described medicinal residues are periplaneta americana medicinal residues after 45-95%v/v ethanol extraction, such as 50 ~ 95%v/v.
Further, described concentration of alcohol is 45 ~ 85%v/v, such as 50 ~ 85%v/v.
Preferably, concentration of alcohol is 65 ± 5%v/v.
Present invention also offers a kind of pharmaceutical composition for the treatment of hepatic injury, it be with periplaneta americana alcohol extraction after medicinal residues be active component or adjuvant, the preparation prepared.
Further, described medicinal residues are periplaneta americana medicinal residues after 45-95%v/v ethanol extraction, such as 50 ~ 95%v/v.
Further, described concentration of alcohol is 45 ~ 85%v/v, such as 50 ~ 85%v/v.
Preferably, concentration of alcohol is 65 ± 5%v/v.
Wherein, described preparation is oral formulations.Such as, tablet, powder, pill, capsule, granule or oral liquid.
In described preparation, also may include pharmaceutically conventional adjuvant or complementary composition.
Pharmaceutically acceptable adjuvant of the present invention includes but are not limited to filler (diluent), lubricant (fluidizer or antitack agent), dispersant, wetting agent, binding agent, regulator, solubilizing agent, antioxidant, antibacterial, emulsifying agent, disintegrating agent etc.Binding agent comprises syrup, arabic gum, gelatin, sorbitol, tragacanth, cellulose and its derivates (as microcrystalline Cellulose, sodium carboxymethyl cellulose, ethyl cellulose or hydroxypropyl methylcellulose etc.), gelatine size, syrup, starch slurry or polyvinylpyrrolidone etc.; Filler comprises lactose, Icing Sugar, dextrin, starch and derivant thereof, cellulose and its derivates, inorganic calcium salt (as calcium sulfate, calcium phosphate, calcium hydrogen phosphate, precipitated calcium carbonate etc.), sorbitol or glycine etc.; Lubricant comprises micropowder silica gel, magnesium stearate, Pulvis Talci, aluminium hydroxide, boric acid, hydrogenated vegetable oil, Polyethylene Glycol etc.; Disintegrating agent comprises starch and derivant (as carboxymethyl starch sodium, Explotab, pregelatinized Starch, modified starch, hydroxypropyl starch, corn starch etc.), polyvinylpyrrolidone or microcrystalline Cellulose etc.; Wetting agent comprises sodium lauryl sulphate, water or alcohol etc.; Antioxidant packages is containing sodium sulfite, sodium sulfite, sodium pyrosulfite, dibutyl benzoic acid etc.; Antibacterial comprises 0.5% phenol, 0.3% cresol, 0.5% chlorobutanol etc.; Regulator comprises hydrochloric acid, citric acid, potassium hydroxide (sodium), sodium citrate and buffer agent (comprising sodium dihydrogen phosphate and sodium hydrogen phosphate) etc.; Emulsifier package containing Tween-80, do not have that sour Pyrusussuriensis is smooth, pluronic gram F-68, lecithin, fabaceous lecithin etc.; Solubilizing agent comprises tween 80, bile, glycerol etc.
Described pharmaceutically acceptable complementary composition, it has certain physiologically active, but adding of this composition can not change above-mentioned food, health product or pharmaceutical composition in disease treatment or to the leading position in human body physiological function improvement process, and only play auxiliary effect, these auxiliary effects are only the utilizations to this composition known activity, are the usual supplementary modes of field of medicaments or healthcare field.
The present invention's research shows that the medicinal residues after periplaneta americana alcohol extraction have therapeutical effect for hepatic injury, particularly alcoholic liver injury, improve the utilization rate of herb resource.
Accompanying drawing explanation
Fig. 1 liver histopathology check result
Detailed description of the invention
Embodiment 1
1 experiment material
1.1 laboratory animal
KM male mice, body weight 18 ~ 22g, by Chengdu, Da Shuo bio tech ltd provides, the laboratory animal quality certification number: scxkc (111) 2008-24.
1.2 Experimental agents
1. (Xinyi Pharmaceutical Co., Ltd., Henan, lot number: 120704) grind Tiopronin enteric-coated tablet, and 0.5% sodium carboxymethyl cellulose solution dissolves, and is made into 2.5mg/mL solution, in suspendible shape; 4 DEG C of Refrigerator stores, the used time shakes up.
2. the preparation of alcohol extraction sample solution:
Sample 1: periplaneta americana (the natural pharmaceutcal corporation, Ltd in Cologne, Sichuan, lot number 120401), 50 DEG C of oven dry, beat powder, pulverize, cross a sieve, get 100g powder, use 85% alcohol reflux, first time adds 7 times amount and extracts 2h, second time adds 5 times amount and extracts 1.5h, third time adds 3 times amount and extracts 1h, merge extractive liquid, leave standstill more than 8h, filter, filtrate recycling ethanol is also condensed into thick paste (relative density about 1.30 (85 DEG C)), add the water of 20 times of extractum amounts, heated and stirred, leave standstill, cooling, oils and fats is fully floated, discard oils and fats, lower floor's solution centrifugal filters, concentrating under reduced pressure and get final product.
Sample 2: get periplaneta americana decoction pieces appropriate, 50 DEG C of oven dry, beat powder, pulverize, get 200g powder, use 45% alcohol reflux, first time adds 10 times amount and extracts 1.5h, second time adds 8 times amount and extracts 1h, third time adds 6 times amount and extracts 1h, merge extractive liquid, leaves standstill more than 8h, filter, filtrate recycling ethanol is also condensed into thick paste (relative density about 1.15 ~ 1.25 (60 DEG C)), adds the water of 30 times of extractum amounts, heated and stirred, leave standstill, cooling, makes oils and fats fully float, discards oils and fats, lower floor solution centrifugal filters, concentrating under reduced pressure and get final product.
Sample 3: get periplaneta americana decoction pieces appropriate, 60 DEG C of oven dry, beat powder, pulverize, cross a sieve, get 500g powder, use 65% alcohol reflux, first time adds 8 times amount and extracts 2h, and second time adds 6 times amount and extracts 1.5h, and third time adds 4 times amount and extracts 1h, merge extractive liquid, leave standstill more than 8h, filter, filtrate recycling ethanol is also condensed into thick paste (relative density about 1.15 ~ 1.25 (60 DEG C)), add the water of 25 times of extractum amounts, heated and stirred, leaves standstill, cooling, oils and fats is fully floated, discard oils and fats, lower floor solution centrifugal filters, concentrating under reduced pressure and get final product.
3. the preparation of medicinal residues sample solution:
After getting above-mentioned periplaneta americana alcohol extraction respectively, powder beaten by medicinal residues, and dissolve with 0.5% sodium carboxymethyl cellulose solution, 4 DEG C of Refrigerator stores, the used time shakes up, and obtains medicinal residues sample solution 1,2,3 successively.
1.3 experimental apparatus and reagent
Electronic balance (Beijing Sai Duolisi balance company limited, model BS-200S-WEI);
Centrifuge (flying pigeon board, model: LXJ-II B);
Numerical control ultrasonic cleaner (Kunshan Ultrasonic Instruments Co., Ltd., model: KQ-500DB);
High-precision electronic meter heavily claims (Foochow Chen Electronics Co., Ltd., model: AWH-30KC);
Chloral hydrate (Chengdu Ke Long chemical reagent factory, product batch number: 20100920, specification: 250g);
Formaldehyde (Chengdu Ke Long chemical reagent factory, product batch number: 20120320, specification: 500ml);
Dehydrated alcohol (Chengdu Ke Long chemical reagent factory, product batch number: 20110820, specification: 500ml);
Sodium chloride injection (Kuming Nanjiang Pharmacy Co., Ltd, product batch number: D101211A2, specification: 500ml:4.5g); 56 ° of Red Star strong, colourless liquor distilled from sorghum, distilled water etc.
2 experiment grouping and administrations
After mice adaptability feeds one week, be divided into 4 groups at random, often organize 10, respectively as: 1. normal group: 0.5% sodium carboxymethyl cellulose solution, 10ml/kg; 2. model group: 0.5% sodium carboxymethyl cellulose solution, 10ml/kg; 3. positive group (tiopronin group): 100mg/kg; 4. 1 group, periplaneta americana alcohol extraction sample; 5. 2 groups, periplaneta americana alcohol extraction sample; 6. 3 groups, periplaneta americana alcohol extraction sample; 7. periplaneta americana medicinal residues sample 1 group: 6.0g/kg; 8. periplaneta americana medicinal residues sample 2 groups: 6.0g/kg; 9. periplaneta americana medicinal residues sample 3 groups: 6.0g/kg.Blank group gives the pure water waiting metering, other groups mice gavage every day 56 ° of Red Star strong, colourless liquor distilled from sorghum 1 time (0.1ml/10g), each group gastric infusion treatment after 3 hours, continuous 10 days
[6].
2.1 observation index detect
After last administration, fasting, after 12 hours, is extractd eyeball of mouse and is got blood, separation of serum.On automatic biochemistry analyzer, measure Serum ALT, AST, GGT are active; Put to death immediately after getting blood, take liver, with 4 DEG C of normal saline flushings, filter paper blots, and weighs, and calculates liver coefficient (liver coefficient: liver weight (g)/body weight (g) × 100%); Getting the maximum leaf of liver is fixed in 10% formalin, and paraffin embedding, section, HE dyeing, basis of microscopic observation hepatic pathology changes.L0% liver homogenate is for detecting MDA, GSH level; L% liver homogenate is for detecting SOD level.
2.2 data processing method
Application SPSS17.0 software carries out statistical analysis.Data are with mean ± standard error
represent, adopt one factor analysis of variance between group, carry out LSD inspection between the neat person's group of variance, heterogeneity of variance person carries out Dunnett ' s T3 and checks.
3 experimental results
3.1 impacts on acute alcohol hepatic injury mouse liver weight coefficient
Table 1 on the impact of acute alcohol hepatic injury mouse liver weight coefficient (n=10,
)
Note: compare with model group, * P<0.05, drug dose is in crude drug, lower same
Table 1 shows, and compares with normal group, and model group mouse liver weight coefficient significantly increases (P<0.05); Explanation modeling success.Compare with model group, medicinal residues each sample group group mouse liver weight coefficient significantly reduces (P<0.05), certain therapeutical effect is described, and ethanol extract group zero difference, ethanol extract is described to alcoholic liver injury substantially without therapeutic effect.
3.2 impacts on alcoholic hepatic injury mice serum ALT, AST, GGT, MDA, SOD
Table 2 is on the impact of acute alcohol hepatic injury mice serum ALT, AST, GGT
Note: compare with model group,
※p<0.05.
Table 2 shows, and compares with blank group, and model group has significant difference (P<0.05), and the Serum ALT of model group mice, AST and GGT value all have remarkable rising (P<0.05), and modeling success is described; Compare with model group, the Serum ALT of the mice of each sample sets of medicinal residues, AST and GGT value all have remarkable reduction (P<0.05), illustrate that periplaneta americana ethanol extract medicinal residues have therapeutical effect to alcoholic liver injury, and ethanol extract is without remarkable reduction, it is described to alcoholic liver injury substantially without therapeutical effect.
Table 3 is on the impact of acute alcohol hepatic injury mice serum SOD, MDA
Note: compare with model group,
※p<0.05.
Table 3 shows, and compares with blank group, and model group has significant difference (P<0.05), and modeling success is described; Compare with model group, all there were significant differences (P<0.05) for SOD, MDA of the mice of each sample sets of medicinal residues, illustrate that periplaneta americana ethanol extract medicinal residues have therapeutical effect to alcoholic liver injury, and ethanol extract is without significant difference, it is described to alcoholic liver injury substantially without therapeutical effect.
3.3 liver histopathology check results
Visible under light microscopic, blank group lobules of liver clear in structure, hepatic cords marshalling, radially arranges, sinus hepaticus and portal area without exception, substantially without inflammatory cell infiltration, hepatocyte form is normal.Model group lobules of liver boundary is unclear, liver rope arrangement disorder, and sinus hepaticus pressurized narrows, and visible vessels is congested, obvious point-like and focal necrosis; Hepatic necrosis, appears that filling the air fat drips, in hepatocyte cloudy swelling.After periplaneta americana alcohol extraction, each dosage medicinal residues group hepatic lesions obviously alleviates, and have and be dispersed in spotty necrosis on a small quantity, swelling of liver cell alleviates, major part hepatocyte structure normal hepatocytes leaflet structure is more clear, hepatic cords marshalling, sinus hepaticus recovers normal substantially, and in endochylema, accidental a small amount of fat drips.Positive group liver structure is roughly normal, and hepatocyte has no obvious tumefaction and necrocytosis, and still visible vessels is congested, sees Fig. 1.
4 conclusions:
By testing discovery above, the medicinal residues after periplaneta americana ethanol extract have certain therapeutical effect for alcoholic liver injury; Wherein, better with the medicinal residues activity after 65 ± 5% ethanol extractions again.
List of references:
[1]Bruhar，Dvoak K，Dousa M，et a1.Alcoholic liver disease[J].Prague Med Rep，2009，110(3):181-190
[2] Zhuan Hui. the epidemiology [J] of alcoholic liver disease. Chinese Journal of Hepatology, 2003,11 (11): 698
[3] Wang Tailing, Zhao Jingbo. the pathology [J] of alcoholic liver disease. gastroenterology and hepatopathy magazine, 1997,6 (1): 4-7
[4] cloud is worn, Zeng Ming, Xiang Pengzhi. the medical value [J] of cockroach. Chinese crude drug, 2005,28 (9): 848-850
[5] Zhang Xuqiang, He Xu etc. the protective effect [J] of American-cockroach-extract C II 13 pairs of rat acute alcoholic liver injuries. Journal of Dali University, 2011,10 (12): 1-5
[6] Miao Liang, Liu Yonghong, Hua Lei. Flos puerariae lobatae alcohol extract is to the research [J] of alcoholism mouse model effect. Chinese Medicine biotechnology, 2009,4 (4): 262-265.
Claims (10)
1. the purposes of medicinal residues in the medicine preparing anti-liver injury after periplaneta americana alcohol extraction.
2. purposes according to claim 1, is characterized in that: described hepatic injury is acute liver damage.
3. purposes according to claim 1 and 2, is characterized in that: described hepatic injury is alcoholic liver injury.
4. the purposes according to claims 1 to 3 any one, is characterized in that: described medicine is the medicine for the treatment of alcoholic liver disease, alcoholic fatty liver, alcoholic hepatitis, alcoholic fibrosis or alcoholic cirrhosis.
5. purposes according to claim 1, is characterized in that: described medicinal residues are periplaneta americana medicinal residues after 45-95%v/v ethanol extraction.
6. purposes according to claim 5, is characterized in that: concentration of alcohol is 45 ~ 85%v/v.
7. purposes according to claim 1, is characterized in that: concentration of alcohol is 65 ± 5%v/v.
8. treat a pharmaceutical composition for hepatic injury, it is characterized in that: it be with periplaneta americana alcohol extraction after medicinal residues be active component or adjuvant, the preparation prepared.
9. pharmaceutical composition according to claim 8, is characterized in that: described medicinal residues are periplaneta americana medicinal residues after 45-95%v/v ethanol extraction.
10. pharmaceutical composition according to claim 9, is characterized in that: concentration of alcohol is 45-85%v/v.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410387622.4A CN104367594B (en) | 2013-08-12 | 2014-08-07 | The new application of the American cockroach alcohol extracting dregs of a decoction |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310349156 | 2013-08-12 | ||
| CN2013103491566 | 2013-08-12 | ||
| CN201410387622.4A CN104367594B (en) | 2013-08-12 | 2014-08-07 | The new application of the American cockroach alcohol extracting dregs of a decoction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104367594A true CN104367594A (en) | 2015-02-25 |
| CN104367594B CN104367594B (en) | 2018-10-16 |
Family
ID=52546955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410387622.4A Active CN104367594B (en) | 2013-08-12 | 2014-08-07 | The new application of the American cockroach alcohol extracting dregs of a decoction |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104367594B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105456520A (en) * | 2015-12-29 | 2016-04-06 | 兖矿集团有限公司总医院 | Pharmaceutical formula for treating alcoholic liver disease and experimental method |
| CN106619730A (en) * | 2016-12-30 | 2017-05-10 | 昆明赛诺制药股份有限公司 | Medicament for treating hepatitis A and preparation method thereof |
| CN106619731A (en) * | 2016-12-30 | 2017-05-10 | 昆明赛诺制药股份有限公司 | Medicine for treating hepatitis C |
| CN107349224A (en) * | 2017-07-17 | 2017-11-17 | 山东巧宾农业科技有限公司 | Application of the blattaria in terms of body fat rate is reduced |
-
2014
- 2014-08-07 CN CN201410387622.4A patent/CN104367594B/en active Active
Non-Patent Citations (2)
| Title |
|---|
| 张旭强 等: "美洲大蠊提取物CII-3对大鼠急性酒精性肝损伤的保护作用", 《大理学院学报》 * |
| 段丽芳: "美洲大蠊提取物抗实验性小鼠纤维化的初步研究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105456520A (en) * | 2015-12-29 | 2016-04-06 | 兖矿集团有限公司总医院 | Pharmaceutical formula for treating alcoholic liver disease and experimental method |
| CN106619730A (en) * | 2016-12-30 | 2017-05-10 | 昆明赛诺制药股份有限公司 | Medicament for treating hepatitis A and preparation method thereof |
| CN106619731A (en) * | 2016-12-30 | 2017-05-10 | 昆明赛诺制药股份有限公司 | Medicine for treating hepatitis C |
| CN106619731B (en) * | 2016-12-30 | 2020-06-12 | 昆明赛诺制药股份有限公司 | Medicine for treating hepatitis C |
| CN106619730B (en) * | 2016-12-30 | 2020-06-16 | 昆明赛诺制药股份有限公司 | Medicine for treating hepatitis A and preparation method thereof |
| CN107349224A (en) * | 2017-07-17 | 2017-11-17 | 山东巧宾农业科技有限公司 | Application of the blattaria in terms of body fat rate is reduced |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104367594B (en) | 2018-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104367594A (en) | New application of drug residues after alcohol extraction of American cockroach | |
| CN104189099A (en) | Application of cistanche phenylethanoid glycoside extractive to control altitude sickness | |
| US20210177923A1 (en) | Panax plant extract and pharmaceutical composition and use thereof | |
| CN103054929A (en) | Rhodiola extract and pharmaceutical composition thereof as well as application of rhodiola extract in treatment of fatty liver disease | |
| CN101869595A (en) | Preparation method and quality detection method of liquorice and gall oral liquid | |
| CN105125566B (en) | The application of mannoglucan aldehydic acid oligosaccharides and derivative in treatment and/or prevention nephrosis medicine or health products is prepared | |
| CN101181373A (en) | Cortex moutan valid target pharmaceutical combination, preparation method and application thereof | |
| CN106138210A (en) | Butterflybush flower and the application of the medicine as preparation treatment hypertensive cardiopathy for the extract thereof | |
| CN102247391B (en) | Application of panax japonicus saponin V to reduction of blood fat | |
| CN102106890B (en) | Applications and preparation method of saussurea total sesquiterpene lactone | |
| CN102247413B (en) | Hypolipidemic effects of radix dipsaci total saponin and akebia stem saponin D | |
| CN101167781A (en) | Orally-administered hypoglycemic sweet potato leaf single prescription traditional Chinese medicine and preparation method thereof | |
| CN105079143A (en) | Medicine composition for treating nephropathy | |
| CN102641342B (en) | A kind of Chinese medicine extract and preparation method for the treatment of nephropathy | |
| CN104042895A (en) | Traditional Chinese medicine composition for treating systemic lupus erythematosus and use thereof | |
| CN108065393A (en) | A kind of food or health food prevented and treat cardiovascular and cerebrovascular disease | |
| CN103908571A (en) | Compound traditional Chinese medicine preparation for treating heart disease | |
| CN107048108A (en) | A kind of preparation method of alkalescent licorice drink | |
| CN101658576B (en) | Purpose of pummelo peel general flavone in preparing medicament for treating alcoholic liver injury | |
| CN102247416B (en) | Blood lipid lowering application of total saponins of panax japonicus | |
| CN106109767A (en) | A kind of compound preparation preventing and treating non-alcohol fatty liver | |
| CN102578579B (en) | Blood sugar and blood lipid regulating health-care food and preparation method thereof | |
| CN104644661A (en) | Application of 20(R)-ginsenoside Rg3 in preparation of medicament for relieving or/and treating hepatitis B and medicament | |
| CN104826049A (en) | Medicated food for preventing and treating atherosclerosis, preparation method and applications thereof | |
| CN102091131B (en) | New application of lotus plumule or extract thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190107 Address after: 615000 Xichang Airport Road, Sichuan Province Patentee after: Sichuan Good Doctor Panxi Pharmaceutical Co., Ltd. Address before: Room 206, Building 5, Gaopeng Avenue, Chengdu High-tech Zone, Sichuan 610041 Patentee before: Chengdu Baicao Heji Technology Co., Ltd. |